Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hisamitsu Pharmaceutical and Kyowa Hakko Kogyo have entered into a joint sales agreement for Japan for a transdermal absorption-type continuous-action drug, HFT-290, which is under development by Hisamitsu to treat cancer pain.
Subscribe to our email newsletter
Under the terms of this agreement, Hisamitsu will obtain a manufacturing and sales approval for the product, and the two companies will subsequently carry out joint sales activities.
After the product will be launched in the market, each company will carry out independent product distribution and information provision or gathering activities under a one-brand, two-channel setup.
HFT-290 is a medicinal narcotic drug preparation that uses fentanyl citrate, a synthetic narcotic, having potent analgesic effects. It has been developed as a tape product, using Hisamitsu’s transdermal drug lelivery system technology. Application for new drug approval is planned to be filed by the end of June 2008.